{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-020850","form_type":"8-K","ticker":"CMPS","cik":"0001816590","company_name":"COMPASS Pathways plc","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.175878+00:00","generated_at":"2026-06-24T04:26:25.545257+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"COMPASS Pathways reports Q2 net loss of $21.0M, appoints Kabir Nath as CEO","bullets":["Net loss for Q2 2022 was $21.0M ($0.50 loss per share) vs $17.5M ($0.44) in Q2 2021.","Cash and cash equivalents of $207.2M at June 30, 2022, down from $273.2M at Dec 31, 2021.","Kabir Nath appointed CEO; George Goldsmith remains Executive Chairman through Dec 2022.","Phase 3 protocols for COMP360 in TRD submitted to FDA, under review; Phase 3 start expected Q4 2022.","Phase 2 study of COMP360 in anorexia nervosa launched across four research sites in the UK and US."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-020850","json":"https://secwatch.observer/filing/0001628280-22-020850.json","markdown":"https://secwatch.observer/filing/0001628280-22-020850.md","text":"https://secwatch.observer/filing/0001628280-22-020850.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816590/000162828022020850/0001628280-22-020850-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816590/000162828022020850/cmps-20220804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:26:25.545257+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}